Exosomal mRNA Vaccine Platform for Multi-Antigen Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines for infectious diseases, particularly SARS-CoV-2, often target a single protein (spike) and may not provide comprehensive immunity, are costly and time-consuming to develop, and lack a platform that mimics the physicochemical state of the intact virus.
Innovation Solution
Development of an exosome-based vaccine platform that delivers mRNA encoding multiple antigens (nucleocapsid and spike proteins) using extracellular vesicles, leveraging both exosomal and cytoplasmic antigen presentation pathways to induce balanced humoral and cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing vaccines target a single protein (spike), then the vaccine development is simpler and faster, but the immunity provided is not comprehensive
Solution Approach 1:
The vaccine divides the viral antigen presentation into multiple segments: exosomal antigens (presented via MHC class I pathway) and cytoplasmic antigens (presented via MHC class II pathway). This segmentation allows simultaneous targeting of multiple immune pathways, providing comprehensive immunity while maintaining a unified vaccine structure that manages complexity through functional organization.
2Reliability
If conventional vaccines are developed, then the development process is established and reliable, but the process is costly and time-consuming
Solution Approach 1:
The vaccine employs preliminary action by pre-organizing antigens into exosomal and cytoplasmic compartments with built-in targeting sequences. This preliminary structuring eliminates the need for complex post-development optimization and multiple trial iterations, reducing development time while maintaining reliability through predetermined functional architecture.
3Reliability
If conventional vaccines are developed, then the development process is established and reliable, but the cost is high
Solution Approach 1:
The vaccine uses synthetic mRNA copies of viral antigens rather than cultivating actual viruses or complex protein assemblies. This copying approach simplifies manufacturing to straightforward mRNA synthesis processes, dramatically reducing costs while maintaining reliability through precise control of antigen sequences and structures.
4Reliability
If the vaccine mimics the intact virus, then the immune response is enhanced, but the risk of using infectious virions increases
Solution Approach 1:
The vaccine extracts only the essential antigenic components (mRNA encoding viral proteins) from the intact virus structure, discarding the infectious viral particle itself. This extraction preserves the immunogenicity of viral antigens while eliminating all infectious risks, as the synthetic mRNA cannot replicate or cause infection.
5Adaptability or versatility
If multiple antigen presentation mechanisms are harnessed, then the immune response is more comprehensive, but the vaccine complexity increases
Solution Approach 1:
The vaccine employs a universal exosomal platform that simultaneously performs multiple functions: housing exosomal antigens for MHC class I presentation, providing cytoplasmic antigens for MHC class II presentation, and facilitating cellular uptake. This multi-functionality achieves comprehensive immune coverage without proportionally increasing structural complexity, as a single exosomal construct accomplishes multiple immunological tasks.
Data Source
AI summary
The present invention relates to modular systems for vaccination against infectious agents that involves the delivery of, e.g., exosome-loaded, antigen-encoding mRNAs to and into cells and tissues of the immunized subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of vaccines, e.g., nucleic acid vaccines, loaded into extracellular vesicles, e.g., exosomes loaded with synthetic mRNAs encoding multiple surface and cytoplasmic antigens of interest, e.g., antigenic polypeptides derived from an infectious virus, e.g., SARS-CoV-2, designed to elicit strong humoral and cellular immune responses due to the simultaneous expression of antigens in their native state and as exosome-associated antigens.